



STATE MEDICAID P&T COMMITTEE MEETING
 THURSDAY, December 15, 2011
 7:00 a.m. to 8:30 a.m.
 Cannon Health Building
 Room 114



MINUTES

Committee Members Present:

Ellie Brownstein, M.D.
 Morgan L. Saylor, PharmD.
 Beth Johnson, R.Ph.
 Julia Ozbolt, M.D.

Kort DeLost, R.Ph.
 Lisa Hunt, R.Ph.
 Bernadette Kiraly, M.D.
 Roger Martenau, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Tim Morley, R.Ph.
 Richard Sorenson, R.N.

Bobbi Hansen, CPhT.

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Gary Oderda, Pharm.D.

Other Individuals Present:

Rachelle Dorr, Alcon
 Greg Bakke, Alcon

Roy Lindfield, Sunovian
 Mark Duddy, Gentech

Meeting conducted by: Ellie Brownstein.

- 1 Review and Approval of Minutes: Kort Delost moved to approve the minutes. Morgan Saylor seconded the motion. The motion was approved unanimously.
- 2 Housekeeping: This will be Morgan Saylor's last meeting, she is moving to Iowa. Lisa Hunt announced that a new PDL will be implemented in January 2012. She also said that she is preparing contract renewals for 2012.
- 3 DUR Board update: No DUR board meeting in December, no updates.
- 4 **Ophthalmic Antibiotics:** Melissa Archer presented an overview of the ophthalmic antibiotics to the committee.

Kort Delost asked if that the research presented suggests polymyxinB/trimethoprim is less effective than the moxifloxacin. Melissa Archer verified it is based off of limited evidence data.

Beth Johnson commented that because 4th generations are used generally for surgery or after, a PA on them would be a barrier to patients. If they get surgery they need that antibiotic. She expresses that some restriction is a good idea and then she asserts that practitioners are restricting usage to those patients needing it for surgery or who have an

infection that does not respond to other treatments. From a patient perspective, what they are using it for, a prior authorization is not appropriate. Bernadette Kiraly commented that if the patient is given a prescription they need to be able to use it immediately rather than wait for a prior authorization to go through. Lisa Hunt asked if the committee would not like to recommend the DUR board look at criteria for a clinical prior authorization, if none is going to be recommended. Beth Johnson agreed that if a prior were required patients would not receive appropriate care (due to the timeframe associated with obtaining a prior authorization). She also points out that utilization does not show high frequency of usage.

Lisa Hunt draws attention to the provided materials and states that she has included other states PDLs for the committee to consider. Bernadette Kiraly stated another point to decide is which agents will have drops versus ointments and preservative free options for sensitive patients.

Bernadette Kiraly asked if the researched showed a difference in the macrolides, erythromycin and azithromycin. Melissa Archer stated that the only evidence available is erythromycin and tobramycin, and they showed to be equal. No clinical research was available for the questioned combination. Bernadette Kiraly stated that azithromycin is available with less frequent dosing increasing compliance. Kort Delost point out that erythromycin ophthalmic ointment is most frequently used. Lisa Hunt verified and referred to the utilization data.

Kort Delost suggested consideration of which agents are available for specific age ranges, or down to a minimum age.

Public Comment: A representative spoke on behalf of moxifloxacin, stating that it is the only agent available down to age 4 months.

Beth Johnson asked if the research mention any allergic reactions to the neomycin products. Melissa Archer responded that there was not much information about adverse reactions noted. Ellie Brownstein stated that the utilization does not show much use of neomycin. Beth Johnson suggested not including neomycin products.

- 5 Board Actions: A motion was made to cover some of the broad spectrum antibiotics, at least one quinolone and ciprofloxacin and polymixin/trimethoprim should be included by Ellie Brownstein. Julia Ozbolt seconded the motion. The motion was approved unanimously.

A motion was made to cover at least an ointment and drop from each category by Ellie Brownstein. Kort Delost seconded the motion. The motion was approved unanimously.

A motion was made to cover a preservative free option by Morgan Sayler. Bernadette Kiraly seconded the motion. The motion was approved unanimously.

A motion was made to cover a 4th generation antibiotic by Beth Johnson. Ellie Brownstein seconded the motion. The motion was approved unanimously.

Next Meeting Set for Thursday, January 19, 2012 – Ophthalmic Anti-inflammatory Drugs
Meeting Adjourned.
Minutes prepared by Bobbi Hansen.